论文部分内容阅读
目的定性和定量地比较了在胶质母细胞瘤病人中分别使用白蛋白结合的血池对比剂钆磷维塞与另一种细胞外对比剂钆布醇后得到的MRI强化效果。方法病理证实为胶质母细胞瘤的35例病人[男25例,年龄(64±14)岁]接受MRI检查,获得对比剂注射前后的T1加权SE影像,包括用相同参数获取注射钆布醇(0.1mmol/kg)5min后、48h后,以及注射钆磷维塞(0.03mmol/kg)5min、3h、6h和24h后的影像。从信噪比(SNR)、对比噪声比(CNR)和对比度增强(CE)三方面定量评价病变范围、轮廓、内部形态、多灶性以及总体诊断倾向。结果 SNR、CNR和肿瘤CE的平均值在注射钆磷维塞后6h最高。在17例病人(48.6%)中发现有多灶性病变,其中12例病人(70.6%)的额外病变在注射钆磷维塞6h后有更明显的强化。在21例病人(60%)中,放射科医生对注射钆磷维塞(κ=0.764)6h后获取的影像总的认可度最高。在22例病人(62.8%)中,比较注射两种对比剂5min后获取的影像显示所有病灶最终定性,钆布醇优于钆磷维塞。结论在早期增强后MR成像中,钆布醇显示了更有意义的肿瘤强化。然而,在注射对比剂后6h获得的影像,钆磷维塞有更好的诊断价值和对比强化。要点①比较了胶质母细胞瘤病人使用钆布醇与钆磷维塞后的MR增强影像。②钆布醇在注射5min后的早期增强成像中显示了较好的强化征象。③钆磷维塞在注射6h后显示了理想的强化征象和最终诊断信息。④钆磷维塞在胶质母细胞瘤对比增强MRI中的诊断质量是有保证的。⑤在不影响影像质量的情况下,使用钆磷维塞可以降低剂量。
OBJECTIVE: To qualitatively and quantitatively compare the MRI enhancement of albumin-bound blood pool contrast agent gadobutrol with gadobutrol with another extracellular contrast agent in glioblastoma patients. Methods Thirty-five patients (25 male, age 64 ± 14 years) with histologically confirmed glioblastoma underwent MR imaging before and after contrast injection of T1-weighted SE images, including the acquisition of gadobutrol with the same parameters (0.1 mmol / kg) for 5 min, 48 h, and injection of gadolinium Virtussis (0.03 mmol / kg) for 5 min, 3 h, 6 h and 24 h. The extent of lesions, contour, internal morphology, multifocality and overall diagnostic tendencies were quantitatively evaluated from three aspects: signal to noise ratio (SNR), contrast to noise ratio (CNR) and contrast enhancement (CE) Results The mean values of SNR, CNR and tumor CE were the highest at 6 h after injection of gadopenterexiviral. In 17 patients (48.6%), multifocal lesions were found, of which 12 (70.6%) had additional lesions that were more pronounced 6 h after GV-P. Of the 21 patients (60%), radiologists had the highest general acceptance of the images taken 6 hours after injection of gadolinium Virtussis (κ = 0.764). In 22 patients (62.8%), images obtained after 5 minutes of injection of both contrast agents showed that all lesions were finally characterized, and gadobutrol was superior to gadopentetate. Conclusion Gadobutrol showed more meaningful tumor enhancement in early post-contrast MR imaging. However, at 6 h after injection of contrast agent, gadopenterexetil has better diagnostic value and contrast enhancement. Points ① Comparison of glioblastoma patients with gadobutrol and gadolinium after VWE MR imaging. ② Gadobutrol in the early enhanced imaging 5min after injection showed a good enhancement signs. ③ Gadolinium Vivasil showed ideal signs of enhancement and final diagnosis after 6 hours of injection. ④ Gd-VW in the contrast-enhanced MRI of glioblastoma in the quality of diagnosis is guaranteed. ⑤ without affecting the image quality of the case, the use of gadolinium phosphorus Vaisala can reduce the dose.